Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease

Kate L. Bowerman, Saima Firdous Rehman, Annalicia Vaughan, Nancy Lachner, Kurtis F. Budden, Richard Y. Kim, David L. A. Wood, Shaan L. Gellatly, Shakti D. Shukla, Lisa G. Wood, Ian A. Yang, Peter A. Wark, Philip Hugenholtz and Philip M. Hansbro ()
Additional contact information
Kate L. Bowerman: The University of Queensland
Saima Firdous Rehman: Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle
Annalicia Vaughan: Thoracic Research Centre, Faculty of Medicine, The University of Queensland, and Department of Thoracic Medicine, The Prince Charles Hospital
Nancy Lachner: The University of Queensland
Kurtis F. Budden: Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle
Richard Y. Kim: Centre for Inflammation, Centenary Institute & University of Technology Sydney, School of Life Sciences, Faculty of Science
David L. A. Wood: The University of Queensland
Shaan L. Gellatly: Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle
Shakti D. Shukla: Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle
Lisa G. Wood: Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle
Ian A. Yang: Thoracic Research Centre, Faculty of Medicine, The University of Queensland, and Department of Thoracic Medicine, The Prince Charles Hospital
Peter A. Wark: Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle
Philip Hugenholtz: The University of Queensland
Philip M. Hansbro: Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, and The University of Newcastle

Nature Communications, 2020, vol. 11, issue 1, 1-15

Abstract: Abstract Chronic obstructive pulmonary disease (COPD) is the third commonest cause of death globally, and manifests as a progressive inflammatory lung disease with no curative treatment. The lung microbiome contributes to COPD progression, but the function of the gut microbiome remains unclear. Here we examine the faecal microbiome and metabolome of COPD patients and healthy controls, finding 146 bacterial species differing between the two groups. Several species, including Streptococcus sp000187445, Streptococcus vestibularis and multiple members of the family Lachnospiraceae, also correlate with reduced lung function. Untargeted metabolomics identifies a COPD signature comprising 46% lipid, 20% xenobiotic and 20% amino acid related metabolites. Furthermore, we describe a disease-associated network connecting Streptococcus parasanguinis_B with COPD-associated metabolites, including N-acetylglutamate and its analogue N-carbamoylglutamate. While correlative, our results suggest that the faecal microbiome and metabolome of COPD patients are distinct from those of healthy individuals, and may thus aid in the search for biomarkers for COPD.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-19701-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19701-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-19701-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().